Experimental cancer pill targets genetic weakness in tumors
Disease control
Terminated
This study tested an experimental oral drug called TNG908 in adults with advanced solid tumors that lack the MTAP gene. The goal was to find a safe dose and see if the drug could shrink tumors. The study was terminated early, so results are limited.
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC